Skip to content
Supriya Lifescience logo

Supriya Lifescience

SUPRIYA NSE
₹859.90 +27.10 (+3.25%)
P/E
34.88
View as Markdown
MCP
Close 4 Nov 2026 ₹859.90 +80.60 +10.3% 1Y
Start ₹779.30

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
25.20%
Debt to Equity
0.00
EPS (TTM)
₹24.65
Book Value
₹148.82
Market Cap
—
P/E (TTM)
34.88
P/B
5.78
ROE
19.10%
Dividend Yield
0.12%
EBITDA
₹306 Cr
52W High
₹1,085.00
52W Low
₹545.50
Day Range
₹820.25 – ₹865.00
Volume
1,18,169

Peer Comparison

Healthcare › Pharmaceuticals

Supriya Lifescience peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Supriya Lifescience (this company)
₹859.9034.88₹6,796 Cr5.780.12%19.10%25.20%₹873 Cr₹198 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr5.280.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

59 Good

Data confidence 100/100

Category scores

Quality
59
Good
Returns, margins, earnings quality 22% weight
Valuation
46
Average
Cheap vs sector & own history 24% weight
Growth
76
Strong
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
50
Average
Trend strength, vol-adjusted 12% weight
Ownership
59
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company is expected to give good quarter

Weaknesses

1
  • Debtor days have increased from 79.6 to 96.8 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish766
OscillatorsBearish360
Moving AveragesStrong Bullish406

Key readings

RSI (14)
48.37
Neutral
MACD (12,26,9)
−12.91
Bearish
SMA (50)
877.21
Bearish
SMA (200)
786.59
Bullish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+16.19%
3Y+21.56%
1Y+18.97%
TTM+28.19%

Net profit

Net profit growth by window
5Y+11.01%
3Y+32.42%
1Y+11.17%
TTM+11.24%

Operating cash flow

Operating cash flow growth by window
5Y+19.60%
3Y+42.71%
1Y+12.73%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−8.62 pp
3Y+7.65 pp
1Y−1.87 pp
TTM−3.64 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹184 Cr
Mar 2018₹213 Cr
Mar 2019₹278 Cr
Mar 2020₹312 Cr
Mar 2021₹391 Cr
Mar 2022₹530 Cr
Mar 2023₹461 Cr
Mar 2024₹570 Cr
Mar 2025₹696 Cr
Mar 2026₹828 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹6.00 Cr
Mar 2018₹9.00 Cr
Mar 2019₹39.00 Cr
Mar 2020₹73.00 Cr
Mar 2021₹124 Cr
Mar 2022₹152 Cr
Mar 2023₹90.00 Cr
Mar 2024₹119 Cr
Mar 2025₹188 Cr
Mar 2026₹209 Cr

Analyst Forecasts

Forecast For
Mar 27 consensus · Price
₹850.00 −10.5% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk medium

Supriya Lifescience is a nearly debt-free API manufacturer that reported FY26 revenue of ₹828 crore (up 19% YoY) and net profit of ₹209 crore, trading at a PE of 37.7x with a market cap of ₹7,362 crore. The company has guided for ₹1,000 crore revenue by FY27, backed by a 55% capacity expansion at its Lote Parshuram facility, though valuation remains elevated and debtor days have stretched to 97 days.

Bull Case 8
  • Nearly debt-free balance sheet with zero secured loans as of FY25, providing financial flexibility for capacity expansion without dilution or interest burden
  • FY26 revenue grew 19% YoY to ₹828 crore from ₹696 crore, demonstrating consistent topline momentum with 3-year sales CAGR of 22%
  • Q4 FY26 revenue surged 50.2% YoY to ₹276.5 crore and PAT jumped 47% YoY to ₹74.2 crore, indicating accelerating growth trajectory
  • Lote Parshuram facility capacity expanded 55% to 932 KLPD after Module E commissioning, providing visible runway toward the ₹1,000 crore FY27 revenue target
  • 3-year compounded profit growth of 33% significantly outpaces the 22% sales CAGR, reflecting operating leverage and margin expansion from 27.4% OPM in FY23 to 35% in FY26
  • Consistent ROE profile averaging 19-20% over 3-5 years and ROCE of 24.3% indicates efficient capital deployment relative to pharma peers
  • Management guidance of over 20% revenue growth for FY27 requires only 21% growth from the FY26 base of ₹828 crore, making the ₹1,000 crore target arithmetically achievable
  • Stock has delivered 33% returns over 1 year and 59% CAGR over 3 years, reflecting strong market re-rating on earnings delivery
Bear Case 7
  • Debtor days have increased from 79.6 to 96.8 days, signaling potential working capital strain or channel stuffing risk as revenue scales
  • OPM contracted from 36.9% in FY25 to 35.0% in FY26, and Q4 FY26 EBITDA margin dipped 142 bps YoY to 35.3%, suggesting margin pressure at higher volumes
  • Price-to-book ratio of 6.58x is demanding; even with reserves of ₹981 crore on a book value of ~₹149 per share, downside risk is significant in a de-rating scenario
  • Dividend yield of just 0.10% with a payout ratio under 4% offers negligible income return, making the stock entirely dependent on capital appreciation
  • Revenue concentration in API/anesthetics segments exposes the company to pricing pressure and regulatory risk in a limited number of therapeutic categories
  • Capital work-in-progress stood at ₹148 crore as of FY25, and ongoing capex at Ambernath and Patalganga carries execution and commissioning timeline risk
  • 52-week high/low data is unavailable, but the stock surged 73% in 3 months, raising the risk of mean-reversion if quarterly results do not sustain the Q4 FY26 run-rate

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Supriya Lifescience faces a significant reputational headwind with its GM Sales & Marketing under judicial custody in an NDPS-related case, which could unsettle investor confidence. On the positive side, the company declared a modest FY26 dividend and promoters maintain unencumbered holdings, signaling stable ownership. The near-term outlook hinges on how the company manages fallout from the NDPS investigation and whether operational performance remains unaffected heading into Q1FY27 results.

Headwinds 1
  • GM faces NDPS judicial custody Jul 4

    GM Sales & Marketing Sreekant Sreedharan granted judicial custody till July 17, 2026, following Customs Department investigation under the NDPS Act. This poses reputational and operational risk.

Positives 1
  • FY26 final dividend declared Jun 23

    Board recommended final dividend of Re 1.00 per share for FY25-26, subject to shareholder approval and TDS provisions.

Neutral 3
  • Promoters hold unencumbered shares Jun 29

    Promoters disclosed zero encumbrance on shares for FY ended March 31, 2026, filed under SEBI takeover regulations.

  • Trading window closed for Q1 Jun 20

    Trading window closed from July 1, 2026, until 48 hours after Q1FY27 results declaration.

  • Analyst and investor meetings held Jun 15

    Virtual analyst meet scheduled June 18 and investor meeting on June 12, 2026, with presentation available on company website.

Quarterly Results

₹ Cr
SUPRIYA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
132
140
140
158
161
166
186
184
145
200
206
277
190
Expenses
88
108
99
103
98
101
120
117
93
127
134
179
142
Operating Profit
44
32
41
56
63
65
66
68
52
73
72
98
47
OPM %
34%
23%
30%
35%
39%
39%
36%
37%
36%
36%
35%
35%
25%
Other Income
3
2
3
2
2
3
2
3
3
3
2
3
3
Interest
1
0
0
1
0
0
1
0
1
0
0
0
0
Depreciation
4
4
4
4
5
5
5
6
6
7
7
8
9
PBT
43
30
40
53
60
62
63
64
47
68
67
92
41
Tax %
33%
20%
26%
31%
25%
26%
25%
21%
27%
26%
26%
19%
41%
Net Profit
29
24
30
37
45
46
47
50
35
50
50
74
24
EPS (₹)
3.54
2.97
3.7
4.59
5.55
5.73
5.81
6.26
4.32
6.27
6.17
9.22
2.99

Profit & Loss

₹ Cr
SUPRIYA profit and loss, annual, ₹ crore
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
184
213
278
312
391
530
461
570
696
828
873
Expenses
166
191
213
213
218
316
332
394
436
533
583
Operating Profit
17
22
65
98
173
214
129
176
261
295
290
OPM %
9%
10%
23%
32%
44%
40%
28%
31%
37%
36%
33%
Other Income
7
9
8
11
5
8
9
11
10
11
11
Interest
12
11
10
7
4
4
3
5
2
3
2
Depreciation
5
5
5
6
7
10
12
16
20
28
31
PBT
8
14
57
96
167
207
123
166
248
275
268
Tax %
30%
40%
31%
24%
26%
27%
27%
28%
24%
24%
—
Net Profit
6
9
39
73
124
152
90
119
188
209
198
EPS (₹)
0.77
1.19
5.39
10.02
16.89
18.86
11.17
14.8
23.35
25.98
24.65
Div. Payout %
0%
0%
0%
20%
3%
3%
5%
5%
4%
4%
—

Balance Sheet

₹ Cr
SUPRIYA balance sheet, annual, ₹ crore
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
15
15
15
15
15
16
16
16
16
16
Reserves
31
40
79
134
254
600
683
799
981
1,182
Borrowings
140
130
90
82
72
27
22
5
5
5
Other Liabilities
55
60
69
105
105
92
98
101
115
154
Total Liabilities
241
245
253
336
445
735
820
921
1,117
1,357
Fixed Assets
89
91
85
99
100
190
262
310
453
689
CWIP
36
34
35
40
79
43
68
149
148
36
Investments
0
0
0
0
0
0
25
64
63
99
Other Assets
117
120
133
197
267
502
466
399
453
534
Total Assets
241
245
253
336
445
735
820
921
1,117
1,357

Cash Flow

₹ Cr
SUPRIYA cash flow, annual, ₹ crore
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
27
28
49
117
76
49
64
113
165
186
Investing
−27
−5
5
−25
−47
−60
−124
−174
−152
−176
Financing
−2
−20
−50
−29
−15
150
−10
−22
−8
−10
Net Cash Flow
−2
3
4
62
15
139
−70
−83
4
0
Free Cash Flow
0
23
54
92
29
−11
−44
−32
2
34
CFO/EBITDA
158
141
97
146
61
51
73
86
86
84

Ratios

SUPRIYA financial ratios, annual
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
99
92
79
60
69
79
67
71
70
97
Inventory Days
113
85
77
130
206
172
234
140
205
229
Days Payable
121
112
110
130
145
91
130
98
129
159
Cash Conversion Cycle
91
64
45
61
130
160
171
114
146
167
Working Capital Days
−69
−50
−5
−40
28
117
168
157
144
147
ROCE %
—
14%
37%
50%
60%
43%
19%
22%
27%
25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Supriya Lifescience insights

67 extracted metrics across FY17–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 68.30%
  • Public 15.43%
  • FIIs 6.44%
  • DIIs 5.47%
  • Others 4.36%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Supriya Lifescience

What does Supriya Lifescience Ltd do?
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
Where is Supriya Lifescience Ltd (SUPRIYA) listed?
Supriya Lifescience Ltd trades as SUPRIYA on the NSE and under code 543434 on the BSE.
Which sector does Supriya Lifescience Ltd belong to?
Supriya Lifescience Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Supriya Lifescience Ltd?
Supriya Lifescience Ltd trades at a PE ratio of 34.88 as of 4 Nov 2026, on earnings per share of ₹24.65, against a book value of ₹148.82 per share.
What is the 52-week high and low of Supriya Lifescience Ltd?
Over the last 52 weeks Supriya Lifescience Ltd has traded between ₹545.5 and ₹1,085 as of 4 Nov 2026.
Does Supriya Lifescience Ltd pay dividends?
Supriya Lifescience Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Supriya Lifescience Ltd?
Supriya Lifescience Ltd reported a return on equity of 19.10%. Its debt-to-equity ratio is 0.00.

Company Information

Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

Website supriyalifescience.com
Listed 28 Dec 2021
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUPRIYA.md for Supriya Lifescience Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month